LabGenius Appoints Dr. Didier Landais as Chief Operating Officer
22.9.2021 07:00:00 EEST | Business Wire | Press release
LabGenius, the machine learning (ML)-driven protein engineering company, has announced the appointment of Didier Landais Ph.D. as Chief Operating Officer. In this role, Didier will leverage his wealth of experience in business and clinical development to lead the commercialization of LabGenius’ drug discovery platform, EVA TM .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005586/en/
LabGenius Appoints Dr. Didier Landais as Chief Operating Officer (Photo: Business Wire)
“I’m delighted that Didier has joined the team,” said Dr. James Field, Founder and CEO of LabGenius. “Didier is a seasoned operator with 30 years of pharmaceutical industry experience and I’m looking forward to working with him as we rapidly grow the company. It’s a testament to the progress we have made at LabGenius and the exciting opportunities we have ahead of us that we were able to attract someone of Didier’s calibre to join us on our journey.”
Didier joins LabGenius from the pharmaceutical company Servier, where he was The Global Head of Licensing. Under his leadership, Servier signed several notable deals including those with Celsius, Oncodesign and Seal Rock. Prior to Servier, Didier spent over 15 years working for biotechnology and pharmaceutical companies at various stages of development in the US.
Speaking about his appointment, Dr. Didier Landais said: “The team at LabGenius has built an impressive machine learning-driven drug discovery platform with huge potential. I am eager to apply my experience and expertise to support the company’s growth.”
– end –
About LabGenius
LabGenius is a leading ML-driven protein engineering company. The company’s discovery platform, EVATM , integrates several cutting-edge technologies drawn from the fields of computer science, robotic automation and synthetic biology. Headquartered in London, UK, the LabGenius team includes experts in protein engineering, synthetic biology, software engineering, data science and robotic automation.
For more information, please visit www.labgeni.us, or connect on Twitter, Facebook, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005586/en/
Contact information
Media enquiries:
Communications Lead
Lucy Shaw
press@labgeni.us
Business development:
Chief Operating Officer
Didier Landais
didier.landais@labgeni.us
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
rhode Continues Its Global Retail Expansion Into Sephora Europe30.4.2026 19:00:00 EEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber, will be available at Sephora online and in most stores across Europe beginning this September, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430569580/en/ rhode continues its global retail expansion into Sephora Europe. rhode’s collection of high-performance, skin-focused products saw strong performance in Sephora U.S. and Canada as the biggest brand launch in the retailer’s history in North America. When launched in November 2025 in the U.K., rhode was also the largest brand launch in Sephora U.K.’s history. “I’m so excited to continue our partnership with Sephora as we launch into retail in Europe, bringing rhode to more of our customers in a physical and I
ABS Acquires RMC Global to Strengthen Cyber, Risk and Resilience Capabilities30.4.2026 18:46:00 EEST | Press release
ABS, through its affiliate ABSG Consulting Inc. (ABS Consulting), has today announced the acquisition of RMC Global (RMC), a leading provider of industrial cybersecurity, risk management and resiliency solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430164690/en/ (L to R): Vince Kuchar, President, RMC Global, and David Wechsler, President and CEO, ABS Group The acquisition strengthens ABS Consulting’s capabilities and market position, bringing together two organizations with complementary expertise, shared values and a common mission. Combining RMC’s capabilities with ABS Consulting’s scale, technical depth and global resources, unlocks more integrated solutions for clients operating in increasingly complex risk environments. ABS Chairman and CEO John McDonald said: “Clients are facing increasing operational risk, cyber threats, and regulatory pressure. Bringing together the expertise of RMC and ABS Consulting s
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 18:00:00 EEST | Press release
Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across the entire IT financial lifecycle - which vendors map to which services, which contracts are approachin
Andersen Consulting Strengthens Digital Transformation Capabilities with Weexa30.4.2026 16:30:00 EEST | Press release
Andersen Consulting enters into a Collaboration Agreement with Weexa, a global provider of digital transformation, B2B integration, and supply chain digitalization solutions. Headquartered in France, Weexa delivers end-to-end services that help organizations streamline, secure, and scale their digital ecosystems. The firm specializes in B2B data-flow management and digitalization, enabling seamless communication between applications both within and across organizations through technologies such as EDI, APIs, and e-invoicing. Weexa also provides SAP integration and supply chain solutions spanning warehouse and transport management, alongside strategic consulting, project delivery, and third-party application maintenance. Serving organizations across the food, retail, wholesale, logistics, transportation, automotive, healthcare, and media sectors, Weexa supports global businesses in optimizing performance while meeting evolving regulatory and digital-compliance requirements. “Collaborati
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 16:22:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom